Navigation Links
Archimedes Pharma Announces Major Fund Raising of GBP65 Million
Date:3/2/2010

ically significant improvements in pain relief versus immediate release morphine, together with high levels of patient acceptability and consistent effectiveness in use.

Jeffrey H. Buchalter has over 20 years experience in the pharmaceutical industry and has held senior positions at a number of multinational pharmaceutical companies. He was most recently President and CEO of Enzon Pharmaceuticals, the US biopharmaceutical company focused on the development, manufacturing and commercialisation of therapies for patients with cancer and other life-threatening conditions. Prior to this, he was CEO of ILEX Oncology, where he led the transformation from a drug development company to a high quality oncology franchise with established commercial operations. He has also held key positions at Pharmacia, Wyeth and Schering Plough.

Simon Turton, Managing Director of Warburg Pincus, said: "We have supported Archimedes since its foundation in 2004 and are delighted to invest again in such an exceptional company as it enters a new stage in its growth. We are particularly pleased to welcome Jeff as President and CEO and to the Board of Archimedes. His vast experience and knowledge of the pharmaceutical industry, and specifically oncology, will be instrumental in accelerating the Company's success through an international platform. This major injection of funding and the appointment of Jeff as the new President and CEO mark the beginning of a new phase in Archimedes' growth plans."


'/>"/>
SOURCE Archimedes Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Texas (PRWEB) December 19, 2014 ... exhibited at the AMSUS Society for Federal Health ... the locum tenens industry to military and federal ... attended the National Veterans Small Business Engagement (NVSBE) ... Tenens continues to be a vital solution in ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... Randy Dotinga HealthDay Reporter ... painkillers, including ibuprofen, might slightly reduce your risk of ... Use of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear ... by 15 percent, the researchers concluded after reviewing nine ... by sun exposure. These painkillers "have ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... issued Global Air Quality Guidelines on Thursday so as to ... each year with most of the deaths occurring in developing ... air quality in the cities. A statement issued by the ... could be saved every year by bringing down the PM10 ...
... in Andhra Pradesh carry the HIV virus, which is passed on ... Society (APSACS) has come to the aid of such infants, suffering ... the society strives to realize infant births sans HIV by the ... the country, the group has lined up the Telugu Network of ...
... (RPCI), the wholly owned subsidiary of Indian pharma major ... with Janssen-Ortho Inc. (JOI) for marketing of its generic ... be commercialised by RPCI, Fentanyl would be sold under ... with Janssen-Ortho Inc, the company said in a statement ...
... and three arms on the Indonesian resort island of Bali ... ,"It's a tough case, but so far they are stable," ... the Bali capital Denpasar, told DPA., ,"We are still ... action yet," he said, adding that in medical terms the ...
... Medical Journal reports that vaccination against the sexually transmitted virus ... in Europe//. ,All the girls of the age ... GlaxoSmithKline or with Gardasil of Merck & Co., according to ... in the U.S. in which, a bill passed by the ...
... Australia are going full steam to counter skin diseases ... aim to prevent the spread of tinea(fungal infections),scabies and ... the ,far flung interior aboriginal communities and to mete ... , ,Poverty and unhygienic living conditions facilitate the ...
Cached Medicine News:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 29 AstraZeneca (NYSE: AZN ) announced today ... Delaware , has found that the substance patent protecting CRESTOR (RE37,314 – the ... no inequitable conduct was committed by any Shionogi employee. The court also held ... , , ...
... CINCINNATI, Ohio , June 29 Dr. Harry ... invited speaker and panel discussion participant at the 2010 Central Regional Meeting ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants ... traditional chemical disciplines.   , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish....
Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
Ergotec Vetriretinal Instrument System. Ultra-fine 2.8 mm jaws. Angled 55 degrees. 20 gauge shaft. 25 mm in length with black tip. Overall length from rear rotation knob to tip....
Medicine Products: